 |
 |
||
    |
 |
||
| Contact UsFAQsHelpful LinksSearch the SiteBusiness DevelopmentCareersHome |
|
Find the product you need: Latest News from Fougera 5.7.2009 Fougera Says New Study on Generic Drug Savings Is Proof that Industry 2.13.2009 Fougera Employees Celebrate 160th Anniversary [ more press releases ] |
 9.30.2005
ALTANA INC ACQUIRES US DERMATOLOGY BUSINESS
Melville, NY, ― September 30, 2005 ― ALTANA Inc, a wholly owned subsidiary of ALTANA Pharma AG, announced today that it has acquired the prescription dermatology business from GlaxoSmithKline Consumer Healthcare, a division of GlaxoSmithKline Corporation (NYSE: GSK). PharmaDerm, a division of ALTANA Inc, will manufacture and market the former GSK products to include: · Aclovate® (alclometasone dipropionate), a synthetic corticosteroid. · Cutivate® (fluticasone propionate), an anti-inflammatory. · Emgel® (erythromycin), an antibiotic. · Oxistat® (oxiconazole nitrate), an anti-fungal. · Temovate® (clobetasol propionate), an anti-inflammatory. “This transaction represents a key acquisition on the branded side of our business and supports the ALTANA Inc specialty business. It is a significant step in the formation of PharmaDerm and toward achieving our goal of becoming the leading pharmaceutical company specializing in dermatology,” said Paul B. McGarty, Chief Executive Officer of ALTANA Inc. The acquisition marks an expansion of PharmaDerm’s current portfolio, which includes flagship products ApexiCon E Cream® (diflorasone diacetate cream USP, 0.05% [emollient]) for steroid responsive dermatoses such as eczema, psoriasis and contact dermatitis and ClindaMax® Lotion (clindamycin phosphate topical suspension USP, 1%), for the treatment of acne. "This acquisition represents our ongoing commitment to expand our business by providing dermatologists with additional solutions for their patients’ needs," said Malcolm McCoy, Vice President of Sales and Marketing at PharmaDerm. “The addition of new product lines allows us to significantly enhance our existing sales and marketing capability and to broaden our offering to the dermatology marketplace.” In March 2005, GlaxoSmithKline received FDA approval for Cutivate® Lotion. Yet to mark its official launch, Cutivate Lotion will add a valuable exclusive asset to PharmaDerm’s product portfolio. "We will move forward with plans to launch Cutivate Lotion this fall and are especially excited about offering dermatologists an effective, mid-potency steroid for their adult and pediatric patients,” McCoy added. Financial terms of the deal were not disclosed. About PharmaDerm PharmaDerm, headquartered in Atlanta, GA is a division of ALTANA Inc, the leading US specialty pharmaceutical manufacturer of topical dermatological prescription products. The company is committed to providing dermatologists with exceptional industry support and offering flexible, easy-to-use and cosmetically elegant products for dermatologists and their patients. The company’s current line of dermatological pharmaceuticals includes ApexiCon E Cream® (diflorasone diacetate cream USP, 0.05% [emollient]), ApexiCon® Ointment (diflorasone diacetate ointment USP, 0.05%), ClindaMax® Lotion (clindamycin phosphate topical suspension USP, 1%), ClindaMax® Gel (clindamycin phosphate gel), and LoKara™ (desonide lotion, 0.05%). For more information on PharmaDerm, please visit the company online at www.pharmaderm.com. About ALTANA Inc ALTANA Inc is one of two U.S. subsidiaries of ALTANA Pharma AG, an international pharmaceutical company headquartered in Germany. ALTANA Inc is the managing group for four divisions including: Fougera and PharmaDerm, which produce topical dermatologic ointments and creams; Pharmaderm Animal Health, a manufacturer of topical preparations for animal care, and Savage Laboratories, marketers of the antidotes CroFabTM and DigiFab® for hospital emergency medicine departments. For more information, call 1-800-432-6673 or log onto www.ALTANAinc.com. # # # Statements about the organization's future expectations, other than historical facts, are "forward looking statements", based on appraisals by the PharmaDerm management and information currently available to PharmaDerm. Factors, which PharmaDerm cannot predict with certainty, may cause actual results to vary substantially from those specifically or implicitly expected in these statements. ®ApexiCon and ClindaMax are registered trademarks, and ™LoKara is a trademark of PharmaDerm, a division of ALTANA Inc. ©2005 PharmaDerm, Norcross, GA. All rights reserved. See product packaging inserts for full prescribing information. |
| Browse the Fougera Product Listing |
|